These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35544095)

  • 1. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
    Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
    Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent
    Stone W; Mahamar A; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Youssouf A; Diallo M; Soumare HM; Kaur H; Lanke K; Ter Heine R; Bradley J; Issiaka D; Diawara H; Traore SF; Bousema T; Drakeley C; Dicko A
    Lancet Microbe; 2022 Jan; 3(1):e41-e51. PubMed ID: 35028628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
    Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN
    Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE;
    Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.
    Poespoprodjo JR; Burdam FH; Candrawati F; Ley B; Meagher N; Kenangalem E; Indrawanti R; Trianty L; Thriemer K; Price DJ; Simpson JA; Price RN
    Lancet Infect Dis; 2022 Mar; 22(3):367-376. PubMed ID: 34710363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial.
    Madanitsa M; Barsosio HC; Minja DTR; Mtove G; Kavishe RA; Dodd J; Saidi Q; Onyango ED; Otieno K; Wang D; Ashorn U; Hill J; Mukerebe C; Gesase S; Msemo OA; Mwapasa V; Phiri KS; Maleta K; Klein N; Magnussen P; Lusingu JPA; Kariuki S; Mosha JF; Alifrangis M; Hansson H; Schmiegelow C; Gutman JR; Chico RM; Ter Kuile FO
    Lancet; 2023 Mar; 401(10381):1020-1036. PubMed ID: 36913959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
    Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H
    Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Chen XC; Jiao DC; Qiao JH; Wang CZ; Sun XF; Lu ZD; Li LF; Zhang CJ; Yan M; Wei Y; Chen B; Feng YQ; Deng M; Ma MD; Plichta JK; He YW; Liu ZZ
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39612919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
    Dawson R; Diacon AH; De Jager V; Narunsky K; Moodley VM; Stinson KW; Liu Y; Zheng B; Hafkin J
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39612928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
    Zhang H; Li Q; Li C; Wu M; Chen H; Li Y; You F; Zhao Y; Jin J; Chen X; Ding Y
    Lancet Rheumatol; 2024 Dec; 6(12):e837-e847. PubMed ID: 39454617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
    Askanase AD; D'Cruz D; Kalunian K; Merrill JT; Navarra SV; Cahuzac C; Cornelisse P; Murphy MJ; Strasser DS; Trokan L; Berkani O
    Lancet Rheumatol; 2025 Jan; 7(1):e21-e32. PubMed ID: 39586304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.
    Curry N; Davenport R; Thomas H; Fox E; Lucas J; Evans A; Massou E; Sharma R; Shanmugaranjan S; Rourke C; Newton A; Deary A; Dallas N; Fitzpatrick-Creamer C; Podbielski JM; Wade CE; Edwards A; Benger J; Morris S; Cotton BA; Piercy J; Green L; Brohi K; Stanworth S
    Health Technol Assess; 2024 Nov; 28(76):1-69. PubMed ID: 39545850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
    Lim AWY; Schneider L; Loy C
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD001747. PubMed ID: 39498781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial.
    Malone A; Kowalski MM; Helliwell J; Lynggaard Boll S; Rovsing H; Moriat K; Castillo Mondragón A; Li Y; Prener Miller C; Reinstrup Bihlet A; Dobek C; Peck V; Wilmink M; Simon LS; Conaghan PG
    Lancet Rheumatol; 2024 Dec; 6(12):e860-e870. PubMed ID: 39401503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.